Familial differential treatment response in schizophrenia lessons from a case of three affected siblings

Pharmacopsychiatry

Volumn 43, Issue 5, 2010, Pages 196-197

  Hoyer, C ^a,b   Kranaster, L ^a,b   Leweke, F M ^a,b   Klosterkotter J ^b   Meyer Lindenberg, A ^a   Koethe, D ^b  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; LORAZEPAM; QUETIAPINE; RISPERIDONE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

ADULT; AGED; ANAMNESIS; CASE REPORT; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FAMILY THERAPY; FEMALE; HUMAN; LETTER; MALE; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DIZYGOTIC TWINS; SIBLING; TWINS;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DISEASES IN TWINS; FEMALE; HUMANS; LORAZEPAM; MALE; SCHIZOPHRENIA; SIBLINGS; SULPIRIDE; TWINS, DIZYGOTIC;

EID: 77954876754     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1248315     Document Type: Letter

References (19)

1. Adams DH, Close S, Farmen M, et al. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2008 23 267-274
2. th edition. Washington DC American Psychiatric Association 1994
3. Andreasen NC, Carpenter WT Jr. Diagnosis and classification of schizophrenia. Schizophrenia Bull 1993 19 199-214
4. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988 145 578-583
5. Chagnon YC, Merette C, Bouchard RH, et al. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004 9 1067-1074
6. de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 2009 59 81-89
7. Gupta M, Bhatnagar P, Grover S, et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009 10 385-397
8. Guy W. Clinical global impression. In: ECDEU Assessment Manual for Psychopharmacology: National Insitute of Mental Health 1976 217-222
9. Harrison PJ. Schizophrenia susceptibility genes and their neurodevelopmental implications: focus on neuregulin 1. Novartis Found Symp 2007 288 246-255 discussion 255249, 276281
10. Ikeda M, Yamanouchi Y, Kinoshita Y, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008 9 1437-1443
11. Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008 18 317-323
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987 13 261-276
13. Lee HY, Kim DJ, Lee HJ, et al. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009 33 276-280
14. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006 163 529-531
15. Malhotra AK, Lencz T, Correll CU, Kane JM. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry 2007 19 523-530
16. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2009 Sep 1 [Epub ahead of print]
17. Murray RM, OCallaghan E, Castle DJ, et al. A neurodevelopmental approach to the classification of schizophrenia. Schizophrenia Bull 1992 18 319-332
18. Need AC, Keefe RS, Ge D, et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009 17 946-957
19. van Os J, Burns T, Cavallaro R, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006 113 91-95